Sonoma Pharmaceuticals (SNOA) Competitors $4.40 +0.41 (+10.28%) Closing price 04:00 PM EasternExtended Trading$4.48 +0.08 (+1.82%) As of 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNOA vs. XCUR, PASG, ENLV, RVPH, IOBT, QTTB, NNVC, PMN, SNYR, and ALLRShould you be buying Sonoma Pharmaceuticals stock or one of its competitors? The main competitors of Sonoma Pharmaceuticals include Exicure (XCUR), Passage Bio (PASG), Enlivex Therapeutics (ENLV), Reviva Pharmaceuticals (RVPH), IO Biotech (IOBT), Q32 Bio (QTTB), NanoViricides (NNVC), Promis Neurosciences (PMN), Synergy CHC (SNYR), and Allarity Therapeutics (ALLR). These companies are all part of the "pharmaceutical products" industry. Sonoma Pharmaceuticals vs. Its Competitors Exicure Passage Bio Enlivex Therapeutics Reviva Pharmaceuticals IO Biotech Q32 Bio NanoViricides Promis Neurosciences Synergy CHC Allarity Therapeutics Exicure (NASDAQ:XCUR) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability and media sentiment. Which has more volatility and risk, XCUR or SNOA? Exicure has a beta of 3.76, meaning that its stock price is 276% more volatile than the S&P 500. Comparatively, Sonoma Pharmaceuticals has a beta of 1.46, meaning that its stock price is 46% more volatile than the S&P 500. Is XCUR or SNOA more profitable? Exicure has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -23.87%. Sonoma Pharmaceuticals' return on equity of -50.00% beat Exicure's return on equity.Company Net Margins Return on Equity Return on Assets ExicureN/A -192.16% -84.30% Sonoma Pharmaceuticals -23.87%-50.00%-16.79% Do analysts prefer XCUR or SNOA? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Sonoma Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has better earnings and valuation, XCUR or SNOA? Sonoma Pharmaceuticals has higher revenue and earnings than Exicure. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioExicure$500K53.97-$9.70M-$3.88-1.10Sonoma Pharmaceuticals$14.91M0.48-$3.46M-$2.46-1.79 Does the media refer more to XCUR or SNOA? In the previous week, Exicure had 3 more articles in the media than Sonoma Pharmaceuticals. MarketBeat recorded 5 mentions for Exicure and 2 mentions for Sonoma Pharmaceuticals. Sonoma Pharmaceuticals' average media sentiment score of 0.50 beat Exicure's score of 0.40 indicating that Sonoma Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exicure 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sonoma Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders hold more shares of XCUR or SNOA? 42.8% of Exicure shares are owned by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are owned by institutional investors. 52.8% of Exicure shares are owned by insiders. Comparatively, 24.6% of Sonoma Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryExicure beats Sonoma Pharmaceuticals on 7 of the 13 factors compared between the two stocks. Get Sonoma Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SNOA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNOA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNOA vs. The Competition Export to ExcelMetricSonoma PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.56M$2.62B$6.16B$10.57BDividend YieldN/A56.38%5.66%4.69%P/E Ratio-1.7924.4085.5827.12Price / Sales0.48744.84612.62135.31Price / CashN/A28.3526.3031.10Price / Book1.615.3712.876.67Net Income-$3.46M$32.78M$3.30B$276.23M7 Day Performance11.68%3.90%4.80%3.31%1 Month Performance-6.98%9.99%8.11%10.76%1 Year Performance58.27%-3.12%75.85%33.58% Sonoma Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNOASonoma Pharmaceuticals1.1138 of 5 stars$4.40+10.3%N/A+43.5%$6.56M$14.91M-1.79180News CoverageAnalyst UpgradeShort Interest ↓Gap UpHigh Trading VolumeXCURExicure1.7564 of 5 stars$4.04+3.5%N/A+54.4%$25.60M$500K-1.0450News CoveragePositive NewsPASGPassage Bio3.3188 of 5 stars$8.12-0.3%$75.67+832.0%-38.8%$25.58MN/A-0.44130News CoverageGap UpENLVEnlivex Therapeutics2.7735 of 5 stars$1.02+1.0%$10.00+880.4%-33.3%$24.90MN/A-1.7770RVPHReviva Pharmaceuticals3.6341 of 5 stars$0.36+17.7%$4.86+1,238.1%-56.4%$24.69MN/A-0.555Analyst UpgradeGap UpHigh Trading VolumeIOBTIO Biotech3.4052 of 5 stars$0.37+0.2%$8.00+2,085.8%-58.1%$24.18MN/A-0.2330Gap UpHigh Trading VolumeQTTBQ32 Bio2.9456 of 5 stars$1.96+0.8%$12.17+522.3%-95.4%$23.91M$1.16M-0.4639Analyst UpgradeNNVCNanoViricides0.2895 of 5 stars$1.43+0.4%N/A-6.1%$22.90MN/A-1.9820PMNPromis Neurosciences2.5883 of 5 stars$0.43-3.4%$4.33+919.6%-54.3%$22.87MN/A-2.025Gap UpSNYRSynergy CHC3.8962 of 5 stars$2.42+0.4%$10.00+313.2%-37.5%$22.85M$34.83M6.3740ALLRAllarity Therapeutics2.6982 of 5 stars$1.55-2.8%$9.25+498.7%-11.9%$22.59MN/A0.0010 Related Companies and Tools Related Companies Exicure Competitors Passage Bio Competitors Enlivex Therapeutics Competitors Reviva Pharmaceuticals Competitors IO Biotech Competitors Q32 Bio Competitors NanoViricides Competitors Promis Neurosciences Competitors Synergy CHC Competitors Allarity Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNOA) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredIs This Warren’s Buffett’s #1 AI Investment?Did you know that Warren Buffett is investing in what Jeff Brown believes will be the next generation of artif...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonoma Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sonoma Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
